Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental chagas disease;Efecto antiparasitario de inhibidores de cistein proteasas in vitro e in vivo en la enfermedad de chagas experimental

Medicina

Volumn 59, Issue SUPPL. 2, 1999, Pages 171-175

  Engel, Juan C ^a,b   Doyle, Patricia S ^a   McKerrow, James H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cruzain; Cysteine protease inhibitors; Trypanosoma cruzi

Indexed keywords

ANTIPROTOZOAL AGENT; CRUZAIN, TRYPANOSOMA CRUZI; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; PROTOZOAL PROTEIN;

ACUTE DISEASE; ANIMAL; C3H MOUSE; CHAGAS DISEASE; CHEMISTRY; CHRONIC DISEASE; DISEASE MODEL; MOUSE; PATHOLOGY; RAT; REVIEW;

ACUTE DISEASE; ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; CHRONIC DISEASE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C3H; PROTOZOAN PROTEINS; RATS;

EID: 0033251034     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Godal T, Nagera J. Tropical Diseases. In WHO Division of Control in Tropical Diseases, 12-13. World Health Organization; Geneva, Switzerland 1990.
2. The National Foundation of Brazil. Etiological treatment for Chagas' disease. Brsilia, Brazil. Parasitol Today 1996; 13: 127-8.
3. Parada H, Carrasco HA, Anez N, Inglessis I. Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study. Int J Cardiology 1997; 60: 49-54.
4. Chagas C. Chagas Carlos: Coletanea de trabalhos cientificos. Editora Universidade de Brasilia 1981; 6: 247-58.
5. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans Royal Soc Trop Med Hyg 1987; 81: 755-9.
6. Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Assessment of cytogenetic damage in chagasic children treated with benznidazole. Mutation Research 1988; 206: 217-20.
7. Kirchhoff LV. American Trypanosomiasis (Chagas' disease)-A tropical disease now in the United States. New Engl J Med 1993; 329: 639-44.
8. Andrade SG, Magalhaes JB, Pontes AL. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull WHO 1985; 63: 721-6
9. Tarleton RL, Zhang L. Chagas' disease etiology: Autoimmunity or parasite persistence? Parasitol Today 1999; 15: 94-9.
10. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Osw Cruz 1991; 86: 187-200.
11. Viotti R, Vigliano C, Armenti H, Segura EL. Treatment of chronic Chagas' disease with benznidazole: Clinical and serological evolution of patients with long-term follow up. Am Heart J 1994; 127: 151-62.
12. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop med Hyg 1998; 59: 526-9.
13. Cazzulo JJ, Cazzulo Franke MC, Martinez J, Franke de Cazzulo BM. Some kinetic properties of a cysteine proteinase (cruzipain) from T. cruzi. Biochem Biophys Acta 1990; 1037: 186-91.
14. Ashall F, Angliker H, Shaw E. Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem Bioph Res Comm 1990; 170: 923-9.
15. Cazzulo JJ, Stoka V, Turk V. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol Chem 1997; 378: 1-10.
16. Eakin AE, McGrath ME, McKerrow JH, Fletterick RJ, Craik CS. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. J Biol Chem 1993; 9: 6115-8.
17. Eakin AE, McKerrow JH, Craik CS. A cysteine protease is a target for the enzyme structure-based design of antiparasitic drugs. Drug Inf J 1995; 92: 1501S-17S.
18. McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS, Fletterick RJ. The crystal structure of cruzain: A therapeutic target for Chagas' disease. J Mol Biol 1995; 247: 251-9.
19. Meirelles MN, Juliano L, Carmona E, Silva SG, Costa EM, Murta ACM, Scharfstein J. Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion arrest the intracellular development of Trypanosoma cruzi in vitro. Mol Bioch Parsitol 1992; 52: 175-84.
20. Harth GN, Andrews N, Mills AA, Engel JC, Smith R, McKerrow JH. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol 1993; 58: 17-24.
21. McKerrow JH, McGrath ME, Engel JC. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design Paras Today 1995; 11: 279-82.
22. McKerrow JH, James MNG. Cysteine proteases: Evolution, function and inhibitor design. In: Perspectives in Drug Discovery and Design 1996; vol. 6, ESCOM, Leiden
23. Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 1998; 111: 597-606.
24. Engel JC, Doyle PS, Hsieh I, McKerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infecticn. J Exp Med 188: 725-34.
25. Roush WR, Gwaltney SL II, Chebg J, Scheidt KA, McKerrow JH, Hansel E. Vinyl sulfonate esters and vinylsulfonamides: Potent, irreversible, inhibitors of cysteine proteases. J Am Chem Soc 1999; 120: 10994-5.
26. Huete-Pérez JA, Engel JC, Brinen LS, Mottram JC, McKerrow JH. Protease trafficking in two primitive eukaryots is nediated by a prodomain protein motiff. J Biol Chem 1999 (In press)
27. McKerrow JH, Engel JC, Caffrey CR. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 1999; 6: 1-6.
28. Seltzer P, Pingel S, Hsieh I, Ugele B, Chan VJ, Engel JC, Russel D, Sakanari JA, McKerrow JH. Cysteine protease inhibitors arrest growth of Leishmania major in vitro and in vivo. Proc Nat Acad Sci 1999. (Sometido a publicación).
29. Scory S, Caffrey CR, Stierhoff YD, Ruppel A, Steverding D. Trypanosoma brucei: killing of blood-stream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-F-A-CHN2. Exp Parasitol 1999. (Sometido a publicación).
30. Semenov A, Olson JE, Rosenthal P. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Ag Chemother 1998; 42: 2254-8.